These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 23098112)

  • 1. Novel aspects of therapy with the dual Src and Abl kinase inhibitor bosutinib in chronic myeloid leukemia.
    Keller-V Amsberg G; Brümmendorf TH
    Expert Rev Anticancer Ther; 2012 Sep; 12(9):1121-7. PubMed ID: 23098112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bosutinib: a dual SRC/ABL kinase inhibitor for the treatment of chronic myeloid leukemia.
    Keller G; Schafhausen P; Brummendorf TH
    Expert Rev Hematol; 2009 Oct; 2(5):489-97. PubMed ID: 21083014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bosutinib: a review of its use in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
    Syed YY; McCormack PL; Plosker GL
    BioDrugs; 2014 Feb; 28(1):107-20. PubMed ID: 24420842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bosutinib: a third generation tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
    Hill BG; Kota VK; Khoury HJ
    Expert Rev Anticancer Ther; 2014 Jul; 14(7):765-70. PubMed ID: 24875651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.
    An X; Tiwari AK; Sun Y; Ding PR; Ashby CR; Chen ZS
    Leuk Res; 2010 Oct; 34(10):1255-68. PubMed ID: 20537386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial.
    Brümmendorf TH; Cortes JE; de Souza CA; Guilhot F; Duvillié L; Pavlov D; Gogat K; Countouriotis AM; Gambacorti-Passerini C
    Br J Haematol; 2015 Jan; 168(1):69-81. PubMed ID: 25196702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects.
    Abbas R; Hug BA; Leister C; Gaaloul ME; Chalon S; Sonnichsen D
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):221-7. PubMed ID: 21691746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bosutinib: a second-generation tyrosine kinase inhibitor for chronic myelogenous leukemia.
    Stansfield L; Hughes TE; Walsh-Chocolaad TL
    Ann Pharmacother; 2013 Dec; 47(12):1703-11. PubMed ID: 24396109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bosutinib : a review of preclinical and clinical studies in chronic myelogenous leukemia.
    Rusconi F; Piazza R; Vagge E; Gambacorti-Passerini C
    Expert Opin Pharmacother; 2014 Apr; 15(5):701-10. PubMed ID: 24479382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
    Remsing Rix LL; Rix U; Colinge J; Hantschel O; Bennett KL; Stranzl T; Müller A; Baumgartner C; Valent P; Augustin M; Till JH; Superti-Furga G
    Leukemia; 2009 Mar; 23(3):477-85. PubMed ID: 19039322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bosutinib: a novel second-generation tyrosine kinase inhibitor.
    Isfort S; Keller-v Amsberg G; Schafhausen P; Koschmieder S; Brümmendorf TH
    Recent Results Cancer Res; 2014; 201():81-97. PubMed ID: 24756786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib.
    Cortes JE; Kantarjian HM; Brümmendorf TH; Kim DW; Turkina AG; Shen ZX; Pasquini R; Khoury HJ; Arkin S; Volkert A; Besson N; Abbas R; Wang J; Leip E; Gambacorti-Passerini C
    Blood; 2011 Oct; 118(17):4567-76. PubMed ID: 21865346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic-pharmacodynamic relationship of bosutinib in patients with chronic phase chronic myeloid leukemia.
    Hsyu PH; Mould DR; Upton RN; Amantea M
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):209-18. PubMed ID: 23070145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation.
    Tanaka R; Kimura S
    Expert Rev Anticancer Ther; 2008 Sep; 8(9):1387-98. PubMed ID: 18759691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bosutinib for the treatment of chronic myeloid leukemia.
    Doan V; Wang A; Prescott H
    Am J Health Syst Pharm; 2015 Mar; 72(6):439-47. PubMed ID: 25736937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
    Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
    Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bosutinib: a review of preclinical studies in chronic myelogenous leukaemia.
    Boschelli F; Arndt K; Gambacorti-Passerini C
    Eur J Cancer; 2010 Jul; 46(10):1781-9. PubMed ID: 20399641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial.
    Cortes JE; Gambacorti-Passerini C; Deininger MW; Mauro MJ; Chuah C; Kim DW; Dyagil I; Glushko N; Milojkovic D; le Coutre P; Garcia-Gutierrez V; Reilly L; Jeynes-Ellis A; Leip E; Bardy-Bouxin N; Hochhaus A; Brümmendorf TH
    J Clin Oncol; 2018 Jan; 36(3):231-237. PubMed ID: 29091516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The safety of Bosutinib for the treatment of chronic myeloid leukemia.
    Kong JH; Khoury HJ; Kim AS; Hill BG; Kota V
    Expert Opin Drug Saf; 2017 Oct; 16(10):1203-1209. PubMed ID: 28774214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL⁺ leukemia cells.
    Nguyen T; Hawkins E; Kolluri A; Kmieciak M; Park H; Lin H; Grant S
    Leuk Res; 2015 Jan; 39(1):65-71. PubMed ID: 25465126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.